Cargando…

Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant

BACKGROUND: Measles, mumps, and rubella (MMR) vaccine is a live-attenuated vaccine usually contraindicated within the first 2 years of hematopoietic cell transplant (HCT). The objective of this study was to assess the safety of MMR vaccine when administered within 2 years of HCT. METHODS: We conduct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desjardins, Michaël, Mitre, Xhoi, Sherman, Amy C, Walsh, Stephen R, Cheng, Matthew P, Kanjilal, Sanjat, Ho, Vincent T, Baden, Lindsey R, Issa, Nicolas C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664685/ https://www.ncbi.nlm.nih.gov/pubmed/34909436 http://dx.doi.org/10.1093/ofid/ofab504

Ejemplares similares

100. Safety Analysis of Live-Attenuated Measles, Mumps, Rubella Vaccine Among Hematopoietic Cell Transplant Recipients Vaccinated Within Two Years of Transplant
por: Mitre, Xhoi, et al.
Publicado: (2021)

Mumps Antibody Response in Young Adults After a Third Dose of Measles-Mumps-Rubella Vaccine
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2014)

Difficulties in Eliminating Measles and Controlling Rubella and Mumps: A Cross-Sectional Study of a First Measles and Rubella Vaccination and a Second Measles, Mumps, and Rubella Vaccination
por: Wang, Zhifang, et al.
Publicado: (2014)

Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation
por: Randi, Bruno Azevedo, et al.
Publicado: (2023)

Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Is it time to reconsider measles, mumps, and rubella immunisation strategies?
por: Boccalini, Sara, et al.
Publicado: (2021)

Measles-Mumps-Rubella Vaccine and COVID-19 Relationship
por: Özdemir, Öner
Publicado: (2020)

Dynamics of the Antibody Response After a Third Dose of Measles-Mumps-Rubella Vaccine Indicate a Slower Decline Compared With a Second Dose
por: Kaaijk, Patricia, et al.
Publicado: (2020)

Tolerability of Early Measles-Mumps-Rubella Vaccination in Infants Aged 6–14 Months During a Measles Outbreak in The Netherlands in 2013–2014
por: van der Maas, Nicoline A. T., et al.
Publicado: (2016)

2467. Timeliness of Childhood Vaccination With the Combination Measles–Mumps–Rubella–Varicella Vaccine vs. the Separate Measles–Mumps–Rubella and Varicella Vaccines in the United States
por: Wolfson, Lara, et al.
Publicado: (2018)

Resurgence risk for measles, mumps and rubella in France in 2018 and 2020
por: Béraud, Guillaume, et al.
Publicado: (2018)

Utility of serological screening for measles, mumps and rubella in immunocompromised patients
por: Sticchi, L, et al.
Publicado: (2019)

Inadequate Measles, Mumps, Rubella, and Varicella Immunity Among Employees
por: Ezeji-Okoye, Stephen, et al.
Publicado: (2021)

Knowledge and Practice of Parents Towards Measles, Mumps and Rubella Vaccination
por: Hussein, Siti Zuhaida, et al.
Publicado: (2022)

Reply to Özdemir, “Measles-Mumps-Rubella Vaccine and COVID-19 Relationship”
por: Fidel, Paul L., et al.
Publicado: (2020)

An Economic Analysis of Mumps Vaccination in Fiji: Static Model Simulation of Routine Measles–Mumps–Rubella (MMR) Vaccination Instead of Current Measles–Rubella (MR) Vaccination
por: Oh, Chunghyeon, et al.
Publicado: (2022)

Partial third nerve palsy after Measles Mumps Rubella vaccination
por: Manzotti, Francesca, et al.
Publicado: (2010)

1548. Risk of Severe Herpes Zoster (HZ) in Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
por: Baumrin, Emily, et al.
Publicado: (2018)

1339 Measles and Mumps Antibody Response in Young Adults after a Third Dose of Measles-Mumps-Rubella Vaccine
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2014)

Comparison of Intralesional Measles, Mumps, Rubella Vaccine and Needling in the Treatment of Recurrent Warts
por: Kolte, Surabhi R., et al.
Publicado: (2020)

Efficacy of intralesional injection of mumps-measles-rubella vaccine in patients with wart
por: Zamanian, Abbas, et al.
Publicado: (2014)

Perspectives on the Measles, Mumps and Rubella Vaccination among Somali Mothers in Stockholm
por: Jama, Asha, et al.
Publicado: (2018)

Measles-mumps-and-rubella-virus-vaccine: Aseptic meningitis: case report
Publicado: (2021)

Measles mumps and rubella virus vaccine: Various toxicities: case report
Publicado: (2022)

Response to Measles, Mumps and Rubella (MMR) Vaccine in Transfusion-Dependent Patients
por: Casale, Maddalena, et al.
Publicado: (2021)

Buschke–Lowenstein tumor treated with intralesional measles, mumps, and rubella vaccine
por: Deshmukh, Ashish, et al.
Publicado: (2022)

Prevalence of Inadequate Immunity to Measles, Mumps, Rubella, and Varicella in MLB and NBA Athletes
por: Conway, Justin J., et al.
Publicado: (2018)

Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients
por: Gold, Jeffrey E., et al.
Publicado: (2020)

Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink
por: Hanson, Kayla E., et al.
Publicado: (2023)

Measles–mumps–rubella vaccination and respiratory syncytial virus-associated hospital contact
por: Sørup, Signe, et al.
Publicado: (2015)

Seroprevalences of Specific IgG Antibodies to Measles, Mumps, and Rubella in Korean Infants
por: Cho, Hye-Kyung, et al.
Publicado: (2016)

Safety of measles, mumps, and rubella vaccine in egg allergy: in vivo and in vitro management
por: Magistà, Stefania, et al.
Publicado: (2020)

1209. Seroprevalence of Measles, Mumps, and Rubella in Korean Healthcare Workers and Strategy for Vaccination
por: Ju Choo, Eun, et al.
Publicado: (2019)

A Nationwide Study on the Seroprevalence of Measles, Mumps, and Rubella in Iranian Children and Adolescents
por: Nokhodian, Zary, et al.
Publicado: (2022)

Are Measles-Mumps-Rubella (MMR) Antibodies Friends or Foes for Covid-19 Disease?
por: Salamony, Azza, et al.
Publicado: (2023)

Anticancer Activity of Measles–Mumps–Rubella MMR Vaccine Viruses against Glioblastoma
por: Khalid, Zumama, et al.
Publicado: (2023)

Seroprevalence of Antibodies to Measles, Mumps, and Rubella among Thai Population: Evaluation of Measles/MMR Immunization Programme
por: Tharmaphornpilas, Piyanit, et al.
Publicado: (2009)

Persistence in Epidemic Metapopulations: Quantifying the Rescue Effects for Measles, Mumps, Rubella and Whooping Cough
por: Metcalf, C. Jessica E., et al.
Publicado: (2013)

1148. Long-term Persistence of Measles and Rubella Virus Neutralizing Antibody Levels among Adults with Three Doses of Measles-Mumps-Rubella Vaccine
por: Alonge, Oluwakemi, et al.
Publicado: (2023)

Seroprevalence of Measles, Mumps, Rubella and Varicella Antibodies in the United States Population, 2009–2010
por: Lebo, Emmaculate J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_657k5jpgb6ck68ukv27go9b4hm